NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Co-Founder Prof. Dr. Laura vanโt Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 - Prof. Dr. Laura van 't Veer, co-founder of Agendia, pioneer in personalized cancer care and co-developer of the MammaPrintยฎ genomic breast cancer recurrence test, Read More
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
This achievement highlights the remarkable seven-year progression of FLEX and its many sub-studies highlighting the ethnic and racial nuances that may influence treatment pathways. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ September 12, 2024 Read More
Agendia Achieves CE-IVDR Certification
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read MoreAgendia Announces JCO Publication on MammaPrint Utility in NRG/NSABP B-42 Trial
MammaPrint 70-gene Assay Evaluated in the NRG Oncology/NSABP B-42 Trial
Read MoreMammaPrint High 2 tumors exhibit heightened immune active state
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreMammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024
Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
Read MoreAgendia to Unveil Robust Suite of Data at 2024 ASCO
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Read More